Envelope-based HIV vaccine peptides as antigens in HIV-1 immunodiagnostics
by Raymond Hewer, Debra Meyer
International Journal of Biotechnology (IJBT), Vol. 9, No. 3/4, 2007

Abstract: Many HIV-1 envelope-based synthetic peptides behave as antigenic mimics of linear or conformational epitopes generated in vivo in infected subjects, meaning they can be used as immunogens for antibody induction in appropriate animal models or as antigens in Enzyme-Linked Immunosorbent Assay (ELISA). These peptides are linear or branched, single sequenced or multi-epitopic, mostly representative of V3 and/or gp41 regions of HIV-1 envelope and when used as ELISA antigens, recognise human or simian retrovirus-induced antibodies. This review details the efficacy of envelope-based synthetic peptides as antigens in HIV diagnostic assays, including those originally designed as vaccine components. The majority of these synthetic peptides, even if based on the V3-loop of HIV-1, are designed to be homogenous. The few heterogeneous peptides prepared through novel synthesis are comparable in behaviour to their homogenous counterparts.

Online publication date: Wed, 27-Jun-2007

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Biotechnology (IJBT):
Login with your Inderscience username and password:

Username:        Password:          Forgotten your password?

Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com